Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/37843| Title: | HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors | Authors: | CUPPENS, Kristof Baas, Paul GEERDENS, Ellen Cruys, Bert FROYEN, Guy Decoster, Lynn THOMEER, Michiel MAES, Brigitte |
Issue Date: | 2022 | Publisher: | Source: | Lung cancer, 170 | Abstract: | Immune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational burden (TMB) by comprehensive next-generation sequencing. | Keywords: | HED;HLA-I diversity;HLA-I evolutionary divergence;Non-small cell lung cancer;PD-1 immunotherapy;TSO500;Tumor mutational burden | Document URI: | http://hdl.handle.net/1942/37843 | ISSN: | 0169-5002 | e-ISSN: | 1872-8332 | DOI: | 10.1016/j.lungcan.2022.05.019 | ISI #: | 000861749300001 | Datasets of the publication: | 10.1016/j.lungcan.2022.05.019 | Rights: | 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2023 |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 1-s2.0-S0169500222004640-main.pdf | Published version | 3.68 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
16
checked on Aug 31, 2025
WEB OF SCIENCETM
Citations
15
checked on Sep 2, 2025
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.